Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Teresa Petrucci

Showing results (1-10 of 175) with videos related to

Pageof 18
Sort By:
Cells|December 18, 2019
The Anti-CD38 Antibody Therapy in Multiple MyelomaMaria Teresa Petrucci, Federico Vozella
Pharmaceuticals (Basel, Switzerland)|November 20, 2020
Introduction to "Immunotherapies for Multiple Myeloma"Massimo Offidani, Maria Teresa Petrucci
Biomolecules|August 26, 2022
Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma TreatmentGianfranco Lapietra, Francesca Fazio, Maria Teresa Petrucci
Mediterranean Journal of Hematology and Infectious Diseases|September 13, 2017
Solitary PlasmacytomaSara Grammatico, Emilia Scalzulli, Maria Teresa Petrucci
Blood and Lymphatic Cancer : Targets and Therapy|July 31, 2019
Managing treatment-related peripheral neuropathy in patients with multiple myelomaSara Grammatico, Laura Cesini, Maria Teresa Petrucci
Expert Opinion on Pharmacotherapy|February 27, 2018
Proteasome inhibitors for the treatment of multiple myelomaEmilia Scalzulli, Sara Grammatico, Federico Vozella, et al.
Patient Preference and Adherence|July 22, 2014
Subcutaneous bortezomib for multiple myeloma treatment: patients' benefitsMaria Teresa Petrucci, Paola Finsinger, Marta Chisini, et al.
Journal of Thrombosis and Thrombolysis|January 8, 2021
Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?Gianfranco Lapietra, Alessandra Serrao, Francesca Fazio, et al.
Leukemia & Lymphoma|June 3, 2014
Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial dataAntonio Palumbo, Massimo Offidani, Francesca Patriarca, et al.
Cancers|June 10, 2023
Belantamab Mafodotin: From Clinical Trials Data to Real-Life ExperiencesSonia Morè, Massimo Offidani, Laura Corvatta, et al.
Pageof 18

Showing results (1-10 of 175) with videos related to

Sort By:
Pageof 18
Cells|December 18, 2019
The Anti-CD38 Antibody Therapy in Multiple MyelomaMaria Teresa Petrucci, Federico Vozella
Pharmaceuticals (Basel, Switzerland)|November 20, 2020
Introduction to "Immunotherapies for Multiple Myeloma"Massimo Offidani, Maria Teresa Petrucci
Biomolecules|August 26, 2022
Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma TreatmentGianfranco Lapietra, Francesca Fazio, Maria Teresa Petrucci
Mediterranean Journal of Hematology and Infectious Diseases|September 13, 2017
Solitary PlasmacytomaSara Grammatico, Emilia Scalzulli, Maria Teresa Petrucci
Blood and Lymphatic Cancer : Targets and Therapy|July 31, 2019
Managing treatment-related peripheral neuropathy in patients with multiple myelomaSara Grammatico, Laura Cesini, Maria Teresa Petrucci
Expert Opinion on Pharmacotherapy|February 27, 2018
Proteasome inhibitors for the treatment of multiple myelomaEmilia Scalzulli, Sara Grammatico, Federico Vozella, et al.
Patient Preference and Adherence|July 22, 2014
Subcutaneous bortezomib for multiple myeloma treatment: patients' benefitsMaria Teresa Petrucci, Paola Finsinger, Marta Chisini, et al.
Journal of Thrombosis and Thrombolysis|January 8, 2021
Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?Gianfranco Lapietra, Alessandra Serrao, Francesca Fazio, et al.
Leukemia & Lymphoma|June 3, 2014
Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial dataAntonio Palumbo, Massimo Offidani, Francesca Patriarca, et al.
Cancers|June 10, 2023
Belantamab Mafodotin: From Clinical Trials Data to Real-Life ExperiencesSonia Morè, Massimo Offidani, Laura Corvatta, et al.
Pageof 18